Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 88 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,353,195 | -15.1% | 1,349,210 | +5.8% | 0.01% | -11.1% |
| Q2 2023 | $8,659,946 | +118.5% | 1,275,397 | +61.2% | 0.01% | +125.0% |
| Q1 2023 | $3,962,689 | +73.3% | 790,956 | +68.8% | 0.00% | +33.3% |
| Q4 2022 | $2,287,080 | +37.4% | 468,664 | +305.8% | 0.00% | +50.0% |
| Q3 2022 | $1,665,000 | +166.0% | 115,490 | +179.0% | 0.00% | +100.0% |
| Q2 2022 | $626,000 | -62.0% | 41,387 | -70.2% | 0.00% | -50.0% |
| Q1 2022 | $1,647,000 | +24.7% | 138,657 | +254.8% | 0.00% | +100.0% |
| Q2 2021 | $1,321,000 | -45.7% | 39,083 | -51.4% | 0.00% | -50.0% |
| Q1 2021 | $2,433,000 | -10.7% | 80,465 | +46.2% | 0.00% | 0.0% |
| Q4 2020 | $2,725,000 | +504.2% | 55,043 | +368.9% | 0.00% | – |
| Q3 2020 | $451,000 | -67.1% | 11,740 | -63.0% | 0.00% | -100.0% |
| Q2 2020 | $1,371,000 | +156.3% | 31,736 | +54.8% | 0.00% | +100.0% |
| Q1 2020 | $535,000 | -65.4% | 20,500 | -58.5% | 0.00% | -50.0% |
| Q4 2019 | $1,545,000 | – | 49,428 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |